GlassScriptPhysician profile
Natasha Mehta
NPI 1124466453
$32,869.95
in general payments reported to CMS, 2019-2025
20 companies · $29K in 2025
The $29K reported for 2025 was more than what 87% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $116 · 2021: $159 · 2022: $149 · 2023: $181 · 2024: $2,275 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $4,989 · Travel and Lodging: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,022.50 |
| Food and Beverage | $4,989.36 |
| Travel and Lodging | $2,244.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24,523.39 | 2024-2025 | Amvuttra, Onpattro |
| Cvrx, INC. | $2,393.55 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,023.38 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $1,133.25 | 2019 | |
| Abbott Laboratories | $604.06 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $505.28 | 2023-2025 | Impella |
| Medtronic, INC. | $359.98 | 2024-2025 | Corevalve Evolut R, Micra |
| Impulse Dynamics (USA) INC. | $251.10 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $178.13 | 2024-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $157.48 | 2023-2025 | |
| Pfizer INC. | $131.71 | 2024 | |
| Bridgebio Pharma, INC. | $120.18 | 2025 | Attruby |
| Allergan, INC. | $117.98 | 2021 | |
| W. L. Gore & Associates, INC. | $83.85 | 2024 | Gore Cardioform Septal Occluder |
| Novartis Pharmaceuticals Corporation | $71.56 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.47 | 2019 | |
| Amgen INC. | $19.58 | 2024 | Repatha |
| Neurocrine Biosciences, INC. | $19.50 | 2024 | Ingrezza |
| Lantheus Medical Imaging, INC. | $17.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.